James M. Frates, an officer of Amylyx Pharmaceuticals, Inc., filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 40,000 shares of common stock to be acquired through the exercise of stock options.

Key Highlights

  • Proposed seller: James M. Frates, identified as an officer of Amylyx Pharmaceuticals, Inc.
  • Shares proposed for sale: 40,000 shares of common stock, with an aggregate market value of $1,180,000.00.
  • Source of shares: Exercise of stock options acquired from the issuer, with the acquisition date and payment date both listed as November 9, 2026, settled in cash.
  • Approximate date of sale: November 9, 2026, through broker Morgan Stanley Smith Barney LLC Executive Financial Services.
  • Shares outstanding: 128,562,904 shares of common stock outstanding, according to the filing.
  • Prior sales: Frates sold 10,810 shares on September 10, 2026, for gross proceeds of $349,820.67 in the preceding three months.
  • Rule 10b5-1 plan: The filing indicates a plan adoption date of April 10, 2026.

Frates Files Rule 144 Notice for Amylyx Option-Derived Stock Sale

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, James M. Frates, listed as an officer of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), proposed to sell 40,000 shares of the company's common stock. The filing lists an aggregate market value of $1,180,000.00 for the proposed sale, with Morgan Stanley Smith Barney LLC Executive Financial Services named as the executing broker at 1 New York Plaza, 8th Floor, New York, NY 10004.

The filing discloses that the shares to be sold were and will be received upon the exercise of stock options granted by the issuer. The acquisition and payment dates are listed as November 9, 2026, with payment made in cash. A remarks section states: "The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale."

In the three months preceding the notice, the filing reports that Frates sold 10,810 shares of common stock on September 10, 2026, generating gross proceeds of $349,820.67. The filing also notes that the sale is being conducted in reliance on a Rule 10b5-1 plan adopted on April 10, 2026. The total shares of common stock outstanding are reported as 128,562,904 as of the filing date.

What Was Disclosed

Amylyx Pharmaceuticals officer James M. Frates filed a Form 144 on November 9, 2026, proposing the sale of 40,000 option-derived common shares valued at $1,180,000.00, executed under a Rule 10b5-1 plan adopted April 10, 2026.